Study 8 of 27Vipivotide literatureNatureTop journal2022
Hundreds of COVID trials could provide a deluge of new drugs.
Not reported in abstract.
Where it sits
this study against the rest of the vipivotide corpus3
Preclinical · this one
17
Observational
1
Open-label
3
Randomised
3
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2022
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Vipivotide corpus
BPSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan.International journal of urology : official journal of the Japanese Urological Association · 2023 · Not reported in abstract.reviewBSurvival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer.JAMA network open · 2026 · n=850 · Median clinical OS was 12.0 months (95% CI, 11.0-13.0) for patients with taxane exposure before Lu-177 PSMA.HumanBCharacterization of Adverse Drug Effects for Three Radiopharmaceuticals: A Descriptive Analysis from WHO-VigiAccess.Cancer biotherapy & radiopharmaceuticals · 2024 · n=17743 · 17,743 ADR reports analyzed.reviewBComparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System).Current oncology (Toronto, Ont.) · 2023 · n=172440 · Cabazitaxel had the highest proportion of serious reports at 86.6% and deaths at 22%.reviewBTargeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · n=27 · RP2D for 177Lu-FAP-2286 monotherapy determined to be 9.25 GBq.HumanBOverall Survival with [177Lu]Lu-PSMA-617 Versus [177Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023 · n=140 · Median OS: [177Lu]Lu-PSMA I&T: 14 mo; [177Lu]Lu-PSMA-617: 15 mo; hazard ratio, 1.18; 95% CI, 0.79-1.78; P = 0.42.Human